Objective To evaluate the clinical efficacy of 125I seeds implantation combined with transcatheter arterial infusion(TAI)in treating advanced pancreatic carcinoma(PC).Methods By using envelope sealing method,76 patients who met enrollment criteria were divided into observation group and control group.Finally,a total of 67 patients were enrolled in this study.The observation group had 31 patients and the patients received 125I seeds implantation combined with TAI therapy,and the control group had 36 patients and the patients received TAI therapy.After 3 courses of treatment,the clinical efficacy,pain score,incidence of obstructive jaundice(OJ),and survival time were compared between the two groups.Results In the observation group and the control group,the objective response rate(ORR)was 48.4％and 25.0％respectively,and the difference was statistically significant(P＜0.05);the disease control rate(DCR)was 83.9％and 66.7％respectively,and the difference was not statistically significant(P＞0.05).In both groups,the postoperative one-month and 3-month pain scores were decreased obviously when compared with the preoperative values(P＜0.05),but the reduction of pain score in the observation group was more obvious than that in the control group(P＜0.05).In the observation group and the control group,the pain relief rates were 23.06％and 13.4％respectively,and the difference was statistically significant(P=0.0252);the incidences of OJ were 19.4％and 50.0％respectively,and the difference was statistically significant(P＜0.05);the median survival time was 7.9 months and 5.1 months respectively,and the difference was statistically significant(P＜0.05).In both groups,the postoperative one-month and 3-month CA199 levels were decreased,and the difference was statistically significant(P＜0.05).No statistically significant difference in the incidences of adverse reactions such as nausea,vomiting,diarrhea and leukopenia existed between the two groups(P＞0.05).Conclusion 125I seeds implantation combined with TAI therapy can effectively relieve cancer pain,prolong survival time in patients with advanced PC,and it is clinically safe.Therefore,this therapy is worthy of clinical promotion.
万方数据